Follow the Oryzon Genomics, S.A. stock price and the full directors' dealings record of the company, a publicly traded company based in Spain. Shares are quoted on the ES market, under the oversight of CNMV. Operating in the Health Care sector, Oryzon Genomics, S.A. has published 8 public disclosures. Market capitalisation: €244.7m. The latest transaction was reported on 8 February 2024 (Other). Among the most active insiders: DOUGLAS FALLER. All data is accessible without an account.
8
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€84,870
1 ops.
Sell Volume
36Σ signal
Buys n/a€84,870 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
10,000 shares@ €2.61100.0% of flowShareXOOFISINISIN ES0167733015CNMV:2022092563
8 of 8 declarations
Acerca de Oryzon Genomics, S.A.
Oryzon Genomics, S.A. es una empresa biofarmacéutica centrada en el desarrollo de terapias innovadoras para el tratamiento de enfermedades neurodegenerativas y cánceres. Cotiza en el mercado XMAD.